Cranpac-D tablet is formulated with Cranberry PAC and D-Mannose. Cranpac-D prevents adhesion of Uro Pathogenic E.Coli (UPEC) through both P-type & Type-1 pili. D-Mannose in Cranpac-D prevents attachment of UPEC on bladder walls, and prevents cystitis (Bladder infections) and
Cranberry prevents attachment of UPEC to the kidney walls, thereby preventing pyelonephritis (Kidney infections).
By preventing urinary tract infections, Cranpac-D can also help reduce the need for antibiotics. Unlike antibiotics which are useful for mainly acute and existing UTIs, Cranpac-D is suitable for prevention as a long-term use.
Unlike antibiotics, Cranpac-D avoids development resistance, secondary infections, side effect and is safe in pregnancy. Cranpac-D is suitable for use in asymptomatic bacteriuria in pregnancy, recurrent cystitis, pyelonephritis, post-coital infections, recurrent UTIs in diabetics, adolescents & peri-post menopausal women
Directions of use:Cranpac-D should be taken 1 tablet twice daily for 3-6 months. Ideally tablet should be taken with plenty of water.
Use under medical supervision
One of the following vendor pharmacies will deliver Cranpac-D Tablet: Health Arx Technologies Private Limited, Amishi Consumer Technologies P Ltd, Organic India Private Limited, Delhi Cryogenic Products Pvt Ltd, First Step Digital Pvt Ltd, Gupta Hom...+more